文献速递血栓与止血

ChAdOx1 nCoV-19疫苗接种后疑似VITT评估的临床诊疗路径

Clinical care pathway for the evaluation of patients with suspected VITT after ChAdOx1 nCoV-19 vaccination.
PubMed 文献 · Blood Adv · 2022-01-01

加拿大不列颠哥伦比亚省制定了省级临床诊疗路径,指导临床医生在腺病毒载体疫苗接种后4至28天内出现血小板减少或血栓症状的患者中评估VITT。2021年5月1日至6月30日期间,68例被评估患者中37%有血栓形成,但仅3例经PF4-ELISA和SRA确诊VITT。有与无VITT患者的血小板计数、d-二聚体水平和ELISA光密度值存在显著差异。

要点

  • 腺病毒载体疫苗接种后4至28天内出现血小板减少或血栓症状应评估VITT。
  • 所有患者均检测PF4抗体ELISA,阳性或d-二聚体≥2.0 mg/L FEU者进一步行改良SRA检测。
  • 确诊VITT患者接受IVIG、非肝素抗凝药和糖皮质激素治疗成功。

核心结论

  • 在被评估VITT的患者中血栓形成常见,PF4-ELISA检测对于确认表现为血栓形成和血小板减少患者的VITT是必要的。

研究设计与样本

  • 加拿大不列颠哥伦比亚省制定的省级临床诊疗路径,指导临床医生评估腺病毒载体疫苗接种后4至28天内出现血小板减少或血栓症状的患者。
  • 2021年5月1日至6月30日期间,共68例患者被评估VITT。

主要发现

  • 68例被评估患者中37%有血栓形成,但仅3例经PF4-ELISA和SRA确诊VITT。
  • 有与无VITT患者的血小板计数、d-二聚体水平和ELISA光密度值存在显著差异。
  • 3例患者有血小板减少和血栓形成伴d-二聚体>4.0 mg/L FEU,但PF4-ELISA和SRA结果阴性。
  • 确诊VITT患者接受IVIG、非肝素抗凝药和糖皮质激素治疗成功。

关键数值与推荐

  • 所有患者均行PF4抗体ELISA检测。
  • 所有PF4-ELISA阳性或d-二聚体≥2.0 mg/L FEU的病例进一步行改良SRA检测血小板活化PF4抗体。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare complication after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) adenoviral vector vaccination. In British Columbia (BC), Canada, a provincial clinical care pathway was developed to guide clinicians in evaluating for VITT among patients who present with thrombocytopenia or thrombosis symptoms within 4 to 28 days after adenoviral vector vaccine exposure. All patients had enzyme-linked immunosorbent assay (ELISA) testing for platelet factor 4 (PF4) antibodies, and all cases with positive PF4-ELISA or d-dimer levels ≥2.0 mg/L fibrinogen equivalent units (FEU) had further testing for platelet-activating PF4 antibodies using a modified serotonin release assay (SRA). Between 1 May and 30 June 2021, 37% of 68 patients investigated for VITT had thrombosis, but only 3 had VITT confirmed by PF4-ELISA and SRA. Platelet counts, d-dimer levels, and ELISA optical density values were significantly different between those with and without VITT. Three patients had thrombocytopenia and thrombosis with d-dimer levels >4.0 mg/L FEU but had negative PF4-ELISA and SRA results. Patients with VITT were treated successfully with IV immunoglobulin, nonheparin anticoagulants, and corticosteroids. Our pathway demonstrated that thrombosis is common among patients investigated for VITT and that PF4-ELISA testing is necessary to confirm VITT in those presenting with thrombosis and thrombocytopenia.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Lee AYY, Al Moosawi M, Peterson EA, et al. Clinical care pathway for the evaluation of patients with suspected VITT after ChAdOx1 nCoV-19 vaccination. Blood Adv. 2022. PMID: 35201292. doi:10.1182/bloodadvances.2021006862

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。